Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal

Molecular diversity of IgG responses to Epstein-Barr virus proteins in asymptomatic Epstein-Barr virus carriers

J Gen Virol.

Goswami R, Shair KHY, Gershburg E

doi: 10.1099/jgv.0.000891.

Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins

J Neuroimmunol.

Lindsey JW

doi: 10.1016/j.jneuroim.

Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas

PLoS One.

Armero VES, Tremblay MP, Allaire A, Boudreault S, Martenon-Brodeur C, Duval C, Durand M, Lapointe E, Thibault P, Tremblay-Létourneau M, Perreault JP, Scott MS, Bisaillon M

doi: 10.1371/

Rheumatoid Arthritis

Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab

BMJ Case Rep.

Ramasamy BR, Charles P, Johnson D, Frauman A

doi: 10.1136/bcr-2017-220184.

Autoimmune DiseaseSystemic Lupus Erythematosus

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals

Ann Rheum Dis.

Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, Kamen DL, Gilkeson GS, Weisman MH, Karp DR, Gaffney PM, Harley JB, Wallace DJ, Norris JM, James JA

doi: 10.1136/annrheumdis-

Epstein-Barr virus: a master epigenetic manipulator

Curr Opin Virol.

Scott RS

doi: 10.1016/j.coviro.2017.07.017.

Rheumatoid Arthritis

Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles

Arthritis Rheumatol

Fechtner S, Berens H, Bemis E, Johnson RL, Guthridge CJ, Carlson NE, Demoruelle MK, Harley JB, Edison JD, Norris JA, Robinson WH, Deane KD, James JA, Holers VM

doi: 10.1002/art.41994

Rheumatoid Arthritis

Epstein-Barr virus and rheumatoid arthritis

Joint Bone Spine.

Balandraud N, Roudier J

doi: 10.1016/j.jbspin.2017.04.011.

Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms

Ann Nucl Med.

Toriihara A, Nakajima R, Arai A, Nakadate M, Abe K, Kubota K, Tateishi U

doi: 10.1007/s12149-017-1180-5.

Related content

Molecular diversity of IgG responses to Epstein-Barr virus proteins in asymptomatic Epstein-Barr virus carriers

Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins

Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas

Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals

Epstein-Barr virus: a master epigenetic manipulator

Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles

Epstein-Barr virus and rheumatoid arthritis

Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms